Auriga Reiterates a 'Buy' on Celgene (CELG); Uneventful Q4 Call; Upsides from Multiple Catalysts in 2012

Auriga reiterates a 'Buy' on Celgene (NASDAQ: CELG) price target of $82.00.

Auriga analyst says, "We expect to see, in 2012, Celgene continue to drive top line growth, largely due to international expansion, improved therapy duration and expanded patient population. Two catalyst likely drive valuation: One is Apremilast Phase III Data, and, the other is the regulatory filing and acceptance of Pomalidomide. Our view about the company has not changed since raising our price target 2 weeks ago."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $72.66 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• AppLovin Corp (APP) PT Lowered to $440 at Benchmark to Reflect Maturing Gaming Business
• Bernstein SocGen: 'Investor day makes us more bullish on SanDisk (SNDK)'